Tango Therapeutics Corp (TNGX) - Gross Sales Margin

Official company branding of Tango Pharma (TNGX)

Tango Therapeutics relies on outsourced manufacturing, focusing on its US-based R&D centers. Selective PRMT5 inhibitors are currently driving performance, while GURU.Markets shows absolute gross margin with a final reading of 0.00, confirming the trend. The company's prospects are based on its synthetic lethality platform, CRISPR technologies, and the success of TNG908 and TNG462 in partnership with Gilead Sciences.

tangotx.com (TNGX) - Gross Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company Tango Therapeutics (TNGX)

- stock value and consensus price forecast:
Fundamental valuation:Tango Therapeutics
Signature product of Tango Therapeutics Corp

Professional capital evaluates Tango Therapeutics (TNGX) through the lens of small molecule synthesis cost efficiency and the implementation of robotic screening. By analyzing gross margin dynamics, the investor identifies the profit share after deducting direct production costs, which allows for an assessment of the scalability of oncology drug development, although even high values do not guarantee the absence of asset volatility.